Skip to main content

Advertisement

SpringerLink
Log in

Should we stop dosing steroids per body surface area for nephrotics?

  • Editorial Commentary
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

In this edition of Pediatric Nephrology, Vaishnavi Raman et al. have published an open-labeled randomized clinical trial of 100 children with idiopathic nephrotic syndrome who were allocated either a body weight- or body surface area-based prednisolone dosing for a duration of 12 weeks. The authors used Kaplan–Meier analysis for comparison of the time to remission. They also compared the relapse rate and found no difference. This editorial discusses the strengths of the current study as well some limitations. The inclusion of relapsing patients in the study protocol is problematic. The follow-up period of only 6 months forms another limitation. No subgroup analysis by age was performed. This editorial also highlights the lack of correlation between steroid dose and steroid exposure and the need for considering the age dependency (ontogeny) of drug disposition. Finally, the need for adherence to CONSORT criteria for reporting randomized controlled clinical trials is emphasized.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Arneil GC (1971) The nephrotic syndrome. Pediatr Clin N Am 18:547–559

    CAS  Google Scholar 

  2. (1984) Minimal change nephrotic syndrome in children: deaths during the first 5 to 15 years’ observation. Report of the International Study of Kidney Disease in Children. Pediatrics 73:497–501. http://www.ncbi.nlm.nih.gov/pubmed/6709428

  3. Filler G (2003) Treatment of nephrotic syndrome in children and controlled trials. Nephrol Dial Transplant 18:vi75–vi78

    Article  CAS  PubMed  Google Scholar 

  4. Hodson EM, Craig JC (2013) Corticosteroid therapy for steroid-sensitive nephrotic syndrome in children: dose or duration? J Am Soc Nephrol 24:7–9

    Article  CAS  PubMed  Google Scholar 

  5. (1981) The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children. J Pediatr 98:561–564. http://www.ncbi.nlm.nih.gov/pubmed/7205481

  6. Ehrich JH, Brodehl J (1993) Long versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft für Pädiatrische Nephrologie. Eur J Pediatr 152:357–361

    Article  CAS  PubMed  Google Scholar 

  7. Ksiazek J, Wyszynska T (1995) Short versus long initial prednisone treatment in steroid-sensitive nephrotic syndrome in children. Acta Paediatr 84:889–893

    Article  CAS  PubMed  Google Scholar 

  8. Lombel RM, Gipson DS, Hodson EM, Kidney Disease: Improving Global Outcomes (2013) Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO. Pediatr Nephrol 28:415–426

    Article  PubMed  Google Scholar 

  9. Hahn D, Hodson EM, Willis NS, Craig JC (2015) Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev 3, CD001533

    PubMed  Google Scholar 

  10. Hiraoka M, Tsukahara H, Haruki S, Hayashi S, Takeda N, Miyagawa K, Okuhara K, Suehiro F, Ohshima Y, Mayumi M (2000) Older boys benefit from higher initial prednisolone therapy for nephrotic syndrome. The West Japan Cooperative Study of Kidney Disease in Children. Kidney Int 58:1247–1252

    Article  CAS  PubMed  Google Scholar 

  11. Haycock GB, Schwartz GJ, Wisotsky DH (1978) Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults. J Pediatr 93:62–66

    Article  CAS  PubMed  Google Scholar 

  12. Mosteller RD (1987) Simplified calculation of body-surface area. N Engl J Med 317:1098

    CAS  PubMed  Google Scholar 

  13. Raman V, Krishnamurthy S, Harichandrakumar KT (2016) Body weight-based prednisolone versus body surface area-based prednisolone regimen for induction of remission in children with nephrotic syndrome: a randomised clinical trial. Pediatr Nephrol. doi:10.1007/s00467-015-3285-1

  14. Schulz KF, Altman DG, Moher D (2010) CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 340:c332

    Article  PubMed Central  PubMed  Google Scholar 

  15. Brooks RJ, Higgins GY, Webster AC (2010) Systematic review of randomized controlled trial quality in pediatric kidney transplantation. Pediatr Nephrol 25:2383–2392

    Article  PubMed  Google Scholar 

  16. Jusko WJ, Rose JQ (1980) Monitoring prednisone and prednisolone. Ther Drug Monit 2:169–176

    Article  CAS  PubMed  Google Scholar 

  17. Colburn WA, Sibley CR, Buller RH (1976) Comparative serum prednisone and prednisolone concentrations following prednisone or prednisolone administration to beagle dogs. J Pharm Sci 65:997–1001

    Article  CAS  PubMed  Google Scholar 

  18. Davis M, Williams R, Chakraborty J, English J, Marks V, Ideo G, Tempini S (1978) Prednisone or prednisolone for the treatment of chronic active hepatitis? A comparison of plasma availability. Br J Clin Pharmacol 5:501–505

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Filler G, Bendrick-Peart J, Strom T, Zhang YL, Johnson G, Christians U (2009) Characterization of sirolimus metabolites in pediatric solid organ transplant recipients. Pediatr Transplant 13:44–53

    Article  CAS  PubMed  Google Scholar 

  20. Filler G, Foster J, Berard R, Mai I, Lepage N (2004) Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation. Transplant Proc 36:1327–1331

    Article  CAS  PubMed  Google Scholar 

  21. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE (2003) Developmental pharmacology—drug disposition, action, and therapy in infants and children. N Engl J Med 349:1157–1167

    Article  CAS  PubMed  Google Scholar 

  22. Hill MR, Szefler SJ, Ball BD, Bartoszek M, Brenner AM (1990) Monitoring glucocorticoid therapy: a pharmacokinetic approach. Clin Pharmacol Ther 48:390–398

    Article  CAS  PubMed  Google Scholar 

  23. Shibasaki H, Furuta T, Kasuya Y (1992) Stable isotope dilution mass spectrometry for the simultaneous determination of cortisol, cortisone, prednisolone and prednisone in plasma. J Chromatogr 579:193–202

    Article  CAS  PubMed  Google Scholar 

  24. Miller PF, Wheeldon J, Brocklebank JT (1987) The separation of unbound prednisolone in plasma by centrifugal ultrafiltration. J Pharm Pharmacol 39:939–941

    Article  CAS  PubMed  Google Scholar 

  25. Gatti G, Perucca E, Frigo GM, Notarangelo LD, Barberis L, Martini A (1984) Pharmacokinetics of prednisone and its metabolite prednisolone in children with nephrotic syndrome during the active phase and in remission. Br J Clin Pharmacol 17:423–431

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. Rocci ML Jr, Assael BM, Appiani AC, Edefonti A, Jusko WJ (1982) Effect on nephrotic syndrome on absorption and disposition of prednisolone in children. Int J Pediatr Nephrol 3:159–166

    PubMed  Google Scholar 

  27. Rostin M, Barthe P, Houin G, Alvinerie M, Bouissou F (1990) Pharmacokinetics of prednisolone in children with the nephrotic syndrome. Pediatr Nephrol 4:470–473

    Article  CAS  PubMed  Google Scholar 

  28. Miller PF, Bowmer CJ, Wheeldon J, Brocklebank JT (1990) Pharmacokinetics of prednisolone in children with nephrosis. Arch Dis Child 65:196–200

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Green OC, Winter RJ, Kawahara FS, Phillips LS, Lewy PR, Hart RL, Pachman LM (1978) Plasma levels, half-life values, and correlation with physiologic assays for growth and immunity. J Pediatr 93:299–303

    Article  CAS  PubMed  Google Scholar 

  30. Sagcal-Gironella AC, Sherwin CM, Tirona RG, Rieder MJ, Brunner HI, Vinks AA (2011) Pharmacokinetics of prednisolone at steady state in young patients with systemic lupus erythematosus on prednisone therapy: an open-label, single-dose study. Clin Ther 33:1524–1536

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  31. Christians U, Schmitz V, Haschke M (2005) Functional interactions between P-glycoprotein and CYP3A in drug metabolism. Exper Opin Drug Metab Toxicol 1:641–654

    Article  CAS  Google Scholar 

  32. Baron S, Raux Demay MC, Vasmant D, Bensman A (1988) Pharmacokinetics of prednisolone in children. Study of a correlation with tolerability and therapeutic effect in nephrosis. Presse Med 17:632–635

    CAS  PubMed  Google Scholar 

  33. Ehrich JH, Geerlings C, Zivicnjak M, Franke D, Geerlings H, Gellermann J (2007) Steroid-resistant idiopathic childhood nephrosis: overdiagnosed and undertreated. Nephrol Dial Transplant 22:2183–2193

    Article  PubMed  Google Scholar 

  34. Samuel S, Scott S, Morgan C, Dart A, Mammen C, Parekh R, Nettel-Aguirre A, Eddy A, Flynn R, Pinsk M, Wade A, Arora S, Benoit G, Bitzan M, Erickson R, Feber J, Filler G, Geier P, Girardin C, Grisaru S, Tee J, Kemp K, Zappitelli M (2014) The Canadian Childhood Nephrotic Syndrome (CHILDNEPH) Project: overview of design and methods. Can J Kidney Health Dis 1:17

    Article  PubMed Central  PubMed  Google Scholar 

  35. Samuel S, Bitzan M, Zappitelli M, Dart A, Mammen C, Pinsk M, Cybulsky AV, Walsh M, Knoll G, Hladunewich M, Bargman J, Reich H, Humar A, Muirhead N (2014) Canadian society of nephrology commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis: management of nephrotic syndrome in children. Am J Kidney Dis 63:354–362

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Schulich School of Medicine & Dentistry, Western University, 800 Commissioners Road East, London, ON, Canada, N6A 5 W9

    Guido Filler

  2. Department of Pathology and Laboratory Medicine, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada, N5A 5A5

    Guido Filler

  3. Department of Medicine, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada, N6A 5 W9

    Guido Filler

  4. Department of Paediatrics, Division of Nephrology, The Hospital for Sick Children, Toronto, ON, Canada

    Lisa A. Robinson

  5. Program in Cell Biology, Hospital for Sick Children, Toronto, ON, M5G 1X8, Canada

    Lisa A. Robinson

  6. Institute of Medical Science, University of Toronto, Toronto, ON, M5S 1A8, Canada

    Lisa A. Robinson

  7. Department of Paediatrics, University of Toronto, Toronto, ON, M5S 2 J7, Canada

    Lisa A. Robinson

Authors
  1. Guido Filler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lisa A. Robinson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Guido Filler.

Ethics declarations

Conflict of interest

The author(s) declare that they have no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Filler, G., Robinson, L.A. Should we stop dosing steroids per body surface area for nephrotics?. Pediatr Nephrol 31, 519–522 (2016). https://doi.org/10.1007/s00467-015-3286-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-015-3286-0

Keywords

Search

Navigation